

FOR IMMEDIATE RELEASE



July 24, 2013

AnGes MG, Inc.

**Completion of NIH RAC Review for the Protocol of
Small-scale Study of Collategene[®]**

AnGes MG, Inc. (AnGes) announced today that its subsidiary, AnGes, Inc., (Maryland, United States [US]) received a notice from that National Institute of Health (NIH) that the Recombinant DNA Advisory Committee (RAC) review of the protocol of the small-scale study of Collategene[®] has been completed. The small-scale clinical study will be conducted as a comprehensive preparation for the global Phase III study of Collategene[®] for the treatment of critical limb ischemia.

The RAC review comprehensively evaluates research studies involving recombinant DNA research from the scientific, medical, safety, ethical, and social aspects. By going through this review, the research studies are ensured by the NIH and widely recognized by specialists in this field.

AnGes Group plans to start the small-scale clinical study as well as complete necessary preparation prior to the initiation of the global Phase III study, with the aim of delivering treatment to patients with critical limb ischemia who currently have no treatment options available.

This event has no effect on business performance for the fiscal year 2013.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

<p>AnGes MG, Inc. Corporate Communications TEL: +81-3-5730-2641, FAX: +81-3-5730-2635 http://www.anges-mg.com</p>
